2024’s Biggest AI Stories
Artificial Intelligence took the industry by storm this year, but how is actually being implemented?
Stock.adobe.com
Huestis discusses the ways that quantum simulation and quantum systems can be used in areas such as drug discovery and the creation and protection of intellectual property in the life sciences industry.
How AI is Changing the Drug Development Journey
While no company has yet achieved the full promise of AI to radically accelerate time to market, meaningful strides are being made across the drug discovery funnel.
As AI continues to dominate the news, maximizing its potential is on every C-suite leader’s mind. Successful AI adoption, specifically in HCP marketing, will require a thoughtful, customer-centric approach to avoid aggravating the promotional fatigue and dissatisfaction fostered by drugmakers' dash toward digital1 since COVID-19. This article provides an overview of some key areas for AI integration that can help improve the HCP customer experience today and tomorrow.
The Impact of Technology on Commercialization: Q&A with Claus Zieler
The Astellas chief commercial officer discusses the impact that the increase in global and local connectivity has had on commercialization, among other trends.
Adoption Lag in AI: Q&A with Scott Snyder
EVERSANA’s chief digital officer discusses the current relationship between pharma and AI.
Beyond the Prescription: Pharma's Role in Digital Health Conversations
April 1st 2025Join us for an insightful conversation with Jennifer Harakal, Head of Regulatory Affairs at Canopy Life Sciences, as we unpack the evolving intersection of social media and healthcare decisions. Discover how pharmaceutical companies can navigate regulatory challenges while meaningfully engaging with consumers in digital spaces. Jennifer shares expert strategies for responsible marketing, working with influencers, and creating educational content that bridges the gap between patients and healthcare providers. A must-listen for pharma marketers looking to build trust and compliance in today's social media landscape.
Talphera Cuts NEPHRO CRRT Study Size, Secures $14.8 Million Private Placement
April 1st 2025The trial size adjustment, along with protocol modifications and the addition of higher-enrollment sites, is expected to facilitate completion of the NEPHRO CRRT study of Niyad in patients undergoing renal replacement therapy by the end of 2025.
